Centre Hospitalier National Dalal Jamm

Dakar, Senegal

Public Hospital, University or Academic Center, Government Research Institution

Serves Western Africa

The Centre Hospitalier National Dalal Jamm (CHNDJ) is a referral hospital located in Guédiawaye, a suburb near Dakar. It is currently one of the largest teaching hospitals in Senegal and serves as a reference center for much of the country and the West African sub-region. It is a hospital inaugurated in 2016 but which has experienced a meteoric development with several services, including the management of adult and childhood cancers, infectious diseases and tropical infectious diseases: gynaecological and neonatal diseases. It also has a large reference laboratory. It is connected to a university research network in Senegal with already clinical trials in basic research.

Le Centre Hospitalier National Dalal Jamm (CHNDJ) est un hôpital de référence situé à Guédiawaye, une banlieue proche de Dakar. Il est actuellement l’un des plus grands hôpitaux universitaires du Sénégal et sert de centre de référence pour une grande partie du pays et de la sous-région ouest-africaine. C’est un hôpital inauguré en 2016 mais qui a connu un développement fulgurant avec plusieurs services, dont la prise en charge des cancers de l’adulte et de l’enfant, des maladies infectieuses tropicales : affections gynécologiques et néonatales. Il dispose également d’un grand laboratoire de référence. Il est connecté à un réseau de recherche universitaire au Sénégal avec déjà des essais cliniques en recherche fondamentale.

Links to previous clinical trials:

N/A

Site Capabilities

Clinical Trial Experience

Therapeutic area interests:

  • Cancer
  • Infectious disease

    • Institution has received grant(s) from:

  • National Funder(s)
  • International Funder(s)

    • Sponsors for previous clinical trials include:

  • Academic
  • Government
  • Industry
  • Investigator-initiated

    • Previous clinical trials conducted:

  • Behavioral
  • Diagnostic
  • Drug – biologic
  • Drug – small molecule
  • Epidemiological
  • Observational
  • Surgical
  • Vaccine

    • Study phase capabilities:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

    • Pediatric research capabilities:

  • Yes

    • Institution Regulatory/Research Ethics Committees

    Frequency of meetings: Quarterly

    Application turnaround time (IRB/IEC): 7-8 weeks

    Average time from receipt of final protocol to review and approval of study by all relevant committees: 7-8 weeks

    Additional compliance:

  • IRB/IEC in compliance with IC E6(R2) in terms of composition, functions, and operations guidelines
  • Institution and/or local regulation mandates the distribution of study safety reports to IRB/IEC

    • Institution Staffing Resources

    Staff typeStaff available (y/n) and specialty experience
    Research coordinatorYes
    Research nurseYes
    Research data managerYes
    -Training in Human Subjects Protection (HSP)
    -Training in Good Clinical Laboratory Practice (GCLP)
    Quality assurance managerYes
    BiostatisticiansYes
    Database programmersYes
    EpidemiologistsYes
    PathologistsYes
    -Training in Good Clinical Laboratory Practice (GCLP)
    PharmacistsYes

    Institution Diagnostic Capabilities

  • Institution has personnel capable of performing diagnostic biopsies

    • Biopsies performed on-site:

  • Core needle biopsy
  • Endoscopic biopsy
  • Fine needle aspirate
  • Liquid biopsy
  • Sentinel lymph node biopsy
  • Skin biopsy
  • Surgical biopsy

    • Laboratory basics:

  • Institution has a laboratory on site
  • Institution sends diagnostic samples to external laboratory
  • Institution’s laboratory has been inspected or audited

    • Laboratory accreditations:

  • None

    • Tests performed on-site:

  • Complete blood count (CBC) with differential
  • Comprehensive metabolic-chemistry panel (CMP)
  • Routine urinalysis
  • Antibody tests
  • Antigen tests
  • Antimicrobial susceptibility and sensitivity
  • Bacterial smear and culture
  • Flow cytometry
  • Fluorescent in situ hybridization (FISH)
  • Fungal culture
  • Genetic testing
  • Histology
  • Immunohistochemistry (IHC)
  • Laboratory-developed tests (LDTs)
  • Microscopy
  • Ova and parasite (O&P) test
  • PCR and/or RT-PCR
  • Other nucleic acid amplification tests (NAATs)
  • Viral culture
  • Viral load

    • Imaging capabilities:

  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI)
  • Positron emission tomography (PET)
  • Nuclear imaging
  • Ultrasound
  • X-ray
  • Pediatric imaging

    • Institution Research Systems, Recordkeeping, and Data Management

  • Institution adheres to informed consent processes compliant with ICH E6(R2)
  • Institution follows ICH E6(R2) for collection and storage of source documentation for paper and/or electronic records
  • Institution stores patient records/source documents (paper/electronic) in a secured, limited access location during and after the trial
  • For source documents collected via electronic data capture, institution has a validated system and site procedures that follow ICH E6(R2) 5.5 guidelines
  • Institution has process in place for proper storage, archiving, and retrieval of essential study document per ICH 8.1
  • Institution study monitors have full access to source documents or certified copies of source documents (if electronic) if direct access can’t be obtained
  • Institution has a finance administration team
  • Institution undergoes routine financial audits

    • Institution Pharmacy

  • Pharmacy on site
  • Pharmacy has secure, limited access storage area with daily temperature monitoring and backup generator
  • Pharmacy has standard processes in place to ensure proper receipt, handling, and storage of investigational study drug/vaccine and comparators
  • Pharmacy has standard processes in place to ensure proper dispensing
  • Pharmacy has standard processes in place to ensure proper labeling that maintains the study blind
  • Pharmacy has standard processes in place to ensure proper drug/vaccine accountability, retrieval, and return or destruction of unused product
  • Institution has a secure, limited-access investigational drug/vaccine storage area with daily temperature monitoring
  • Institution’s pharmacy has a backup generator sufficient to run necessary equipment, refrigerators, freezers, etc.

    • Institution Equipment

  • Protocol for managing anaphylactic shock
  • Institution has a blood bank
  • Institution carries out blood transfusions for patients that need it
  • Functioning IV infusion pumps
  • Functioning basic life support equipment (crash cart)
  • Functioning electrocardiogram (EKG)

    • Availability of banked blood at institution:

  • Always available
  • Occasionally available
  • Rarely available

    • Institution performs the following routine blood screening tests on banked blood:

  • HIV
  • HBV
  • HCV
  • HPV
  • HTLVI
  • HTLVII
  • Syphilis

    • Additional information:

  • Institution’s equipment is calibrated and maintained per manufacturer’s guidelines
  • Institution’s equipment calibration and maintenance is documented
  • Institution’s laboratory has a secure, limited access biological specimen storage area with daily temperature monitoring
  • Institution’s laboratory has a backup power source, with alarm, sufficient to run necessary equipment, refrigerators, freezers, etc.
  • Institution maintains and uses a diagnostic imaging protocol manual
  • Laboratory maintains and uses a laboratory protocol manual
  • Laboratory maintains and uses a laboratory protocol manual

    • Program-Specific Capabilities

    Institution Cancer Treatment Capabilities and Equipment

  • Treats cancer patients
  • Performs surgical excisions
  • Administers chemotherapy
  • Uses radiation therapy

    • Radiotherapy machines on site:

  • Linear accelerator
  • Cobalt 60
  • Brachytherapy machine

    • Institution Infectious Disease Treatment Capabilities and Equipment

  • Treats infectious disease patients
  • Protocol for managing sepsis

    • Vaccines administered on site:

  • Unknown

    • Infectious disease treatment services performed on site:

  • Antimicrobial/antibiotic drugs (small molecules or biologics; including antibacterial, antifungal, antiparasitic, antiviral medicines)
  • Immunotherapies:
  • Supportive care/symptom management
  • Surgery
  • Viral load monitoring

    • Investigators at Centre Hospitalier National Dalal Jamm

    Abibatou Sall, Ph.D.

    Head of Biological Hematology

  • Cancer

    • Overview

    Dr. Sall is the Head of Biological Hematology at Centre Hospitalier National Dalal Jamm. She is responsible for the hospital’s Hematology and Laboratory departments, including blood bank and diagnostic capabilities. She has expertise in laboratory quality assurance; molecular techniques (including fluorescence in situ hybridization [FISH], next-generation sequencing [NGS], and PCR); pathology; and pediatric oncology (laboratory and genetic focus). Dr. Sall’s clinical trial interests include diagnostic, epidemiological, genetic (mapping and testing), and observational studies for hematologic malignancies.

    Formal Clinical Trial Training*

  • Formal GCLP Training

    • Trial Phases

  • Phase I
  • Phase III
  • Phase II

    • Experience Conducting or Participating in Clinical Trials: Yes

    Previous Clinical Trials:

    -Trial: COVID-19 drug efficacy and epidemiology study in Senegal.

    -Principal investigator: Prof. Louise Fortes, Centre Hospitalier National Dalal Jamm.

    -Dr. Sall’s role in trial: Processing of samples, laboratory testing, and patient follow-up with diagnostics.

    *Definitions

    HSP – Human Subjects Protection

    GCP – Good Clinical Practice

    GCLP – Good Clinical Laboratory Practice